Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anaptysbio Inc

23.75
-0.1300-0.54%
Post-market: 23.750.00000.00%14:41 EDT
Volume:211.54K
Turnover:5.04M
Market Cap:697.79M
PE:-4.96
High:24.13
Open:23.65
Low:23.51
Close:23.88
Loading ...

Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Relay Therapeutics (RLAY) and Inspire Medical Systems (INSP)

TIPRANKS
·
07 May

AnaptysBio Is Maintained at Buy by Guggenheim

Dow Jones
·
06 May

AnaptysBio (ANAB) Receives a Buy from Wedbush

TIPRANKS
·
06 May

AnaptysBio price target raised to $54 from $52 at Guggenheim

TIPRANKS
·
06 May

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relay Therapeutics (RLAY) and AnaptysBio (ANAB)

TIPRANKS
·
06 May

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

Zacks
·
06 May

AnaptysBio Q1 EPS $(1.28) Misses $(1.25) Estimate, Sales $27.77M Beat $15.27M Estimate

Benzinga
·
06 May

BRIEF-AnaptysBio Q1 Net Income USD -39.329 Million

Reuters
·
06 May

AnaptysBio Q1 Operating Expenses USD 55.31 Million

THOMSON REUTERS
·
06 May

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
06 May

AnaptysBio Price Target Maintained With a $40.00/Share by Wedbush

Dow Jones
·
01 May

Wells Fargo Sticks to Their Buy Rating for AnaptysBio (ANAB)

TIPRANKS
·
22 Apr

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

GlobeNewswire
·
17 Apr

CloroxPro™ launches second year of the HealthyClean™ Trained Specialist and now Trained Manager Course for Centennial College Students

CNW Group
·
07 Apr

AnaptysBio Shares Jump on Buyback Program Authorization

Dow Jones
·
25 Mar

AnaptysBio Approves $75 Million Buyback Plan; Shares Rise

MT Newswires Live
·
24 Mar

Anaptys Announces Stock Repurchase Plan

THOMSON REUTERS
·
24 Mar

Anaptys Announces Stock Repurchase Plan

GlobeNewswire
·
24 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: AnaptysBio (ANAB), Cytokinetics (CYTK) and uniQure (QURE)

TIPRANKS
·
06 Mar

AnaptysBio Is Maintained at Overweight by JP Morgan

Dow Jones
·
05 Mar